B. Metzler seel. Sohn & Co. Holding AG Purchases Shares of 1,262 Bio-Rad Laboratories, Inc. (NYSE:BIO)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,262 shares of the medical research company’s stock, valued at approximately $422,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in BIO. First Eagle Investment Management LLC increased its holdings in Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after purchasing an additional 634,311 shares in the last quarter. Swedbank AB bought a new position in shares of Bio-Rad Laboratories during the first quarter worth about $1,824,000. Principal Financial Group Inc. raised its position in Bio-Rad Laboratories by 95.6% in the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after buying an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. lifted its stake in Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after acquiring an additional 84,237 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its position in Bio-Rad Laboratories by 320.6% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 3,663 shares of the medical research company’s stock worth $1,000,000 after acquiring an additional 2,792 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Trading Up 2.3 %

Shares of NYSE:BIO opened at $332.91 on Monday. The company has a 50-day simple moving average of $340.52 and a 200 day simple moving average of $316.27. The company has a market capitalization of $9.32 billion, a P/E ratio of -12.18 and a beta of 0.93. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. During the same quarter in the prior year, the business earned $2.33 EPS. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on BIO shares. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective on the stock. Royal Bank of Canada increased their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Citigroup lifted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average target price of $391.80.

Insider Buying and Selling

In related news, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. The trade was a 80.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 28.41 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.